Gao-Jun Teng
Nanjing, China
Location status: Recruiting
Location contact
Gao-Jun Teng, MD
CONTACT
NCT Number: NCT06593964
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Nanjing, China
Location status: Recruiting
Gao-Jun Teng, MD
CONTACT
This is a prospective, multicenter, randomized controlled, non-inferiority design trial. Participants who meet the criteria will be randomly assigned into the experimental group or the control group,with a ratio of 1:1. In the experimental group the Thermosensitive Nanogel Embolic Agent will be used in the TACE procedure, while in the control group the Embosphere microspheres will be used. The primary endpoint is disease control rate of the target lesions at 1 month after the last TACE treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Thermosensitive Nanogel Embolic Agent
Time frame: One month after the last TACE
Probability of target lesion control, evaluated by the investigator and independent image review committee respectively (mRECIST).
Time frame: One month after the last TACE
Success rate of target lesion embolization, evaluated by the investigator and independent image review committee respectively.
Time frame: One month after the last TACE treatment
Objective response rate of target lesions, evaluated by the investigator and independent image review committee respectively (mRECIST).
Time frame: Three and six months after the first TACE
Probability of target lesion control, evaluated by the investigator and independent image review committee respectively (mRECIST).
Time frame: One month after the first TACE
(Intraoperative imaging ability, microcatheter delivery capacity) evaluated by the investigator.
Time frame: Up to 24 months
Rate of adverse events, evaluated by the investigator (CTACE 5.0)
Contact information is provided by the study sponsor or research team.
Zhongda Hospital
Other
Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07227012
Adenocarcinoma, Advanced Hepatocellular Carcinoma
Los Angeles, California, United States
View Trial DetailsNCT03942328
Adenocarcinoma, Carcinoma
Rochester, Minnesota, United States
View Trial DetailsNCT07679061
Adenocarcinoma, Carcinoma
Minato-ku, Tokyo, Japan
View Trial DetailsNCT05269381
Adenocarcinoma, Anatomic Stage III Breast Cancer AJCC v8
Jacksonville, Florida, United States
View Trial Details